Document Fragment View
Fragment Information
Showing contexts for: erectile dysfunction in Vifor International Ltd & Anr. vs Corona Remedies Pvt Ltd & Anr. on 7 February, 2024Matching Fragments
The name of the medicinal product itself may either be a single, 'invented' name (trade name) or a common or scientific name, usually the INN of the active substance (s), accompanied by a trademark or the name of the Marketing Authorisation holder. For applications using the CP, guidance on invented names and the procedure for submitting them for acceptance is available on the EMA website.‖ Pharmaceuticals Biotechnology and the Law (2nd Edition) - Trevor Cook ―Non-proprietary names 14.6 The full chemical name for a medicinal product is usually long and complex and it has been recognised that its use is not desirable for proper communication in medicine and the labelling and promotion of pharmaceuticals. Indeed most biological molecules are of such complexity that they cannot be given a chemical name in the conventional sense. There is thus a need for a relatively simple name by which a particular pharmaceutical is referred to, but one which is not a trade mark, so that for example the drug as sold by others than the original patentee can be identified after patent expiry. Thus the practice has developed of providing drugs with at least two names other than their full chemical name; one, a non-proprietary, or generic, name which is free for all to use in respect of the drug in question and the other a brand name specific to each manufacturer which that manufacturer registers as a trade mark and which he has the exclusive right to use. For example, VIAGRA is Pfizer's trade mark for the erectile dysfunction drug the generic name of the active moiety for which is sildenafil, but the full chemical name for which moiety is 4-[2-ethoxy-5-(4- methy;piperazin-1-yl)sulfonyl-pheyl]-0-methyl-7-propyl- 3,5,8,9-tetrazabicyclo [4.3.0] nona-3,7,10-trien-2-one. Sildenafil has other utilities, and thus REVATIO is Pfizer's trade mark for the same active moiety, but as formulated and supplied for the treatment of pulmonary arterial hypertension. Once patent protection for sildenafil expires it will be possible for others to trade in sildenafil not of Pfizer's manufacture, and to call it this, but they will still not be able to use Pfizer's trade marks for it.‖ Pharmaceutical, Biotechnology, and Chemical Inventions: